2019 Future of Microscopic Polyangiitis (MPA) R&D Pipeline Drugs and Companies- Analysis of Global Microscopic Polyangiitis (MPA) Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

January 2019 | 45 pages | ID: 26AEDD0A241EN
VPAResearch

Abstracts

The global demand for Microscopic Polyangiitis (MPA) treatment options is emerging rapidly driven by consumption in major emerging markets. As more growth opportunities will turn up over the medium to long term future, a large number of companies are working on Microscopic Polyangiitis (MPA) pipeline. Companies quickly adapting to the change and moving their products to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and inadequate financial support are holding some of the Microscopic Polyangiitis (MPA) pipeline companies from advancing their products into Phase 3 or Phase 4.

Microscopic Polyangiitis (MPA) Report Description

The H1 2019 pipeline review report on Microscopic Polyangiitis (MPA) pipeline is a comprehensive study on the candidates in development across different phases worldwide. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Microscopic Polyangiitis (MPA) pipeline compounds.

The Microscopic Polyangiitis (MPA) pipeline guide presents information on all active drugs currently being developed for Microscopic Polyangiitis (MPA). The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Microscopic Polyangiitis (MPA) pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Microscopic Polyangiitis (MPA) drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Microscopic Polyangiitis (MPA) product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Microscopic Polyangiitis (MPA) pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Microscopic Polyangiitis (MPA) pipeline report includes

• An overview of Microscopic Polyangiitis (MPA) disease including symptoms, causes, diagnosis and available treatment options is provided.
• Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc
• Phase wise count of pipeline compounds
• Company wise list of pipeline compounds
• Mechanism of Action wise pipeline compounds
• For each pipeline product, the following details are provided-
• Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)
• Current status of development
• Drug overview
• Mechanism of Action
• Pre-clinical and Clinical Trials

REASONS TO BUY

• The report is designed to help industry executives promote the success and continued growth of their organizations
• Get clear understanding of the entire Microscopic Polyangiitis (MPA) pipeline, with details on active projects
• Stay ahead of the competition through comprehensive knowledge of Microscopic Polyangiitis (MPA) pipeline progress
• Get in detail information of each product with updated information on each project along with key milestones
• Gain clear insights into the market through in-depth strategic analysis review
• Know the list of companies participating in global Microscopic Polyangiitis (MPA) pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
• Get trial information for each pipeline product under development
• Understand the pipeline structure in terms of mechanism of Action, phase and company

The report will be delivered in 2 working days.

Contents

1. TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2. GLOBAL MICROSCOPIC POLYANGIITIS (MPA) PIPELINE OVERVIEW

2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Report Guide and Research Methodology

3. EXECUTIVE SUMMARY

3.1 Microscopic Polyangiitis (MPA) Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development (Pre-clinical, Discovery, Phase 1 and Phase 2)
3.3 Pipeline Drugs in Advanced Stage of Development (Phase 3, Pre-registration)
3.4 Companies involved in Microscopic Polyangiitis (MPA) pipeline, H1- 2019
3.5 Mechanism of Action wise Microscopic Polyangiitis (MPA) Pipeline Candidates

4. CELLTRION INC MICROSCOPIC POLYANGIITIS (MPA) PIPELINE DETAILS

4.1 Celltrion Inc Business Profile
4.2 Celltrion Inc Microscopic Polyangiitis (MPA) Drug Details
  4.2.1 Drug Snapshot
    4.2.1.1 Originator
    4.2.1.2 Collaborator/Co-Developer
    4.2.1.3 Route of Administration
    4.2.1.4 Orphan Drug/Fast Track/Special Designation
    4.2.1.5 Area
    4.2.1.6 Type of Molecular Entity
4.3 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments

5. CHEMOCENTRYX INC MICROSCOPIC POLYANGIITIS (MPA) PIPELINE DETAILS

5.1 ChemoCentryx Inc Business Profile
5.2 ChemoCentryx Inc Microscopic Polyangiitis (MPA) Drug Details
  5.2.1 Drug Snapshot
    5.2.1.1 Originator
    5.2.1.2 Collaborator/Co-Developer
    5.2.1.3 Route of Administration
    5.2.1.4 Orphan Drug/Fast Track/Special Designation
    5.2.1.5 Area
    5.2.1.6 Type of Molecular Entity
5.3 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments

6. INFLARX MICROSCOPIC POLYANGIITIS (MPA) PIPELINE DETAILS

6.1 InflaRx Business Profile
6.2 InflaRx Microscopic Polyangiitis (MPA) Drug Details
  6.2.1 Drug Snapshot
    6.2.1.1 Originator
    6.2.1.2 Collaborator/Co-Developer
    6.2.1.3 Route of Administration
    6.2.1.4 Orphan Drug/Fast Track/Special Designation
    6.2.1.5 Area
    6.2.1.6 Type of Molecular Entity
6.3 Current Status
6.4 Drug Overview
6.5 Drug Mechanism of Action
6.6 Clinical/Pre-clinical Trial Details
6.7 Latest Drug Developments

7. SANDOZ INTERNATIONAL GMBH MICROSCOPIC POLYANGIITIS (MPA) PIPELINE DETAILS

7.1 Sandoz International GmbH Business Profile
7.2 Sandoz International GmbH Microscopic Polyangiitis (MPA) Drug Details
  7.2.1 Drug Snapshot
    7.2.1.1 Originator
    7.2.1.2 Collaborator/Co-Developer
    7.2.1.3 Route of Administration
    7.2.1.4 Orphan Drug/Fast Track/Special Designation
    7.2.1.5 Area
    7.2.1.6 Type of Molecular Entity
7.3 Current Status
7.4 Drug Overview
7.5 Drug Mechanism of Action
7.6 Clinical/Pre-clinical Trial Details
7.7 Latest Drug Developments

8. TEIJIN PHARMA LTD MICROSCOPIC POLYANGIITIS (MPA) PIPELINE DETAILS

8.1 Teijin Pharma Ltd Business Profile
8.2 Teijin Pharma Ltd Microscopic Polyangiitis (MPA) Drug Details
  8.2.1 Drug Snapshot
    8.2.1.1 Originator
    8.2.1.2 Collaborator/Co-Developer
    8.2.1.3 Route of Administration
    8.2.1.4 Orphan Drug/Fast Track/Special Designation
    8.2.1.5 Area
    8.2.1.6 Type of Molecular Entity
8.3 Current Status
8.4 Drug Overview
8.5 Drug Mechanism of Action
8.6 Clinical/Pre-clinical Trial Details
8.7 Latest Drug Developments

9. TTY BIOPHARM COMPANY LTD MICROSCOPIC POLYANGIITIS (MPA) PIPELINE DETAILS

9.1 TTY Biopharm Company Ltd Business Profile
9.2 TTY Biopharm Company Ltd Microscopic Polyangiitis (MPA) Drug Details
  9.2.1 Drug Snapshot
    9.2.1.1 Originator
    9.2.1.2 Collaborator/Co-Developer
    9.2.1.3 Route of Administration
    9.2.1.4 Orphan Drug/Fast Track/Special Designation
    9.2.1.5 Area
    9.2.1.6 Type of Molecular Entity
9.3 Current Status
9.4 Drug Overview
9.5 Drug Mechanism of Action
9.6 Clinical/Pre-clinical Trial Details
9.7 Latest Drug Developments

10. LATEST MICROSCOPIC POLYANGIITIS (MPA) DRUG PIPELINE DEVELOPMENTS, 2019

11. APPENDIX

11.1 About Us
11.2 Sources and Methodology
11.3 Contact Information